AMR Conference 2020

4th AMR Conference 2020

Digital conference week 24–28 August 2020

What was different for the AMR Conference 2020?​

In view of the continuing uncertain situation and travel restrictions due to the COVID-19 pandemic, we implemented the 4th AMR Conference as a digital format in the week of 24–28 August 2020.

The global health crisis caused by COVID-19 shows more than ever the importance of infectious diseases expertise and the high need for further fighting against antimicrobial resistance (AMR). A cross-sectoral international dialogue with all stakeholders involved will be crucial to help implement innovative therapies and diagnostics in the clinical practice globally.

Together with our supporters – among others our major partner, the BEAM Alliance – the AMR Conference will continue to provide a (virtual) platform for those debates bringing together stakeholders from industry, SMEs, start-ups, academia, clinics, investors, public institutions and policy. Within our digital AMR Conference Week in August, we caught up discussing the challenges of bringing new antimicrobial treatments and diagnostics into the market.

Five days of insights and networking for the global AMR community: Each conference day covered a focus topic with selected LIVE sessions and high-level panels. Additionally, participants were able to explore scientific poster presentations, participate in virtual 1:1 meetings throughout the whole week and to engage within our new digital AMR stakeholder platform.

Here are some key takeaways from the Closing Session:​

“I want us all at the finishing line,” highlighted Dame Sally in her keynote speech, reminding us all that with the continuing AMR crisis #wearethelobster slowly getting boiled unless we act together now.
Dame Sally DaviesUK Special Envoy on Antimicrobial Resistance, UK Department of Health and Social Care
“Europe has to step up and set up a pan-European strategy to incentivize innovation in AMR product development and commercialization,” said Marc Gitzinger on behalf of BEAM Alliance, referring to a post conference papersupported by further stakeholders such as NOVO REPAIR IMPACT FUND, GARDP, the Antimicrobials Working Group, the BIO organisation, IFPMA and Pfizer and more.
Marc GitzingerCEO, BioVersys AG & Vice President Board, BEAM Alliance
“Policy needs to put legislation on the table,” urged Tiemo Woelken from the European Parliament MEP Interest Group on AMR. He is also calling for the EU commission to put AMR on the agenda of the European pharmaceutical strategy which is currently discussed.
Tiemo WoelkenMember of the European Parliament
“Our problem can’t be solved by a country-by-country basis. This takes too much time. Joint action in Europe is needed,” said Evan Loh, CEO Paratek and representing the Antimicrobial Working Group in the US.
Evan LohMD, CEO, Paratek & Chair, Antimicrobials Working Group
“AMR is a hidden pandemic and COVID-19 has shown us that political will can drive innovation.”
Catharina Böhme CEO, FIND
Previous
Next

Highlights – Digital AMR Conference 2020

The #AMRconference 2020 was a great success. Almost 450 international AMR experts have participated in 26 live sessions which provided a 360 degree overview of the current AMR industry and resulted in engaging discussions.
These relevant topics in human and animal health were covered in the live sessions:
  • Lessons learned from COVID-19
  • Business models & policy incentives
  • Global markets
  • Financing & investing
  • Outlook & roadmap
  • Focus on therapeutics
  • Focus incentives, reimbursement, regulatory aspects and markets
  • Focus on animal health
  • Focus on diagnostics
  • Start-up pitches
  • SME Campus (therapeutics and diagnostics)